Future Oncology · 2016 · 39 citations · 24 references
MedicineOncologySurgeryNeuro-oncologyOncologic SurgerySurgical OncologyBrain TumorsCancer Survival AnalysisGlioblastomaNeuro-oncologic SurgeryRecurrent Brain TumorsGlioblastoma PrognosisGlioblastoma SurgeryGlioma SurgeryOverall Survival After RecurrencePrognostic Factors AnalysisPrognostic Models For RecurrenceRecurrent Tumor Surgery
BACKGROUND: The most appropriate management of recurrent glioblastoma is still controversial. In particular, the role of surgery at recurrence remains uncertain. PATIENTS & METHODS: From our Institutional data warehouse we analyzed 270 consecutive patients who received second surgery for recurrent glioblastoma, to assess survival after second surgery, and to evaluate prognostic factors. RESULTS: Complete resection was found in 128 (47.4%) and partial resection in 142 patients (52.6%). Median survival from second surgery was 11.4 months (95% CI: 10.0-12.7). Multivariate analysis showed that age (p = 0.001), MGMT methylation (p = 0.021) and extent of surgery (p < 0.001) are associated with better survival. CONCLUSION: A complete resection should be the goal for second resection and younger age and MGMT methylation status might be considered in the selection of patients.
24
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp, Warren Mason, Martin J. van den Bent et al. · New England Journal of Medicine · 2005 · 21.6K citations · Full text
Roger Stupp, Monika E. Hegi, Warren Mason et al. · The Lancet Oncology · 2009 · 7.8K citations
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman, Michael D. Prados, Patrick Y. Wen et al. · Journal of Clinical Oncology · 2009 · 2.4K citations
Medicine, Oncology, Pharmacology +17
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
James J. Vredenburgh, Annick Desjardins, James E. Herndon et al. · Journal of Clinical Oncology · 2007 · 1.4K citations · Full text
Medicine, Oncology, Pharmacotherapy +17